Rättelse: SenzaGens delårsrapport januari-juni 2026 Ι Fortsatt stark utveckling i Q2 2026 med 13 % tillväxt och positivt kassaflöde
Correction: SenzaGen’s interim report January–June 2026 | Continued strong development in Q2 2026 – 13% growth with positive cash flow
SenzaGens delårsrapport januari-juni 2026 | Fortsatt stark utveckling i Q2 2026 med 13% tillväxt och positivt kassaflöde
SenzaGen’s interim report January–June 2026 | Continued strong development in Q2 2026 – 13% growth with positive cash flow
SenzaGen’s subsidiary receives two orders within non-animal testing with a total value of SEK 2.4 million